Jun Wei

Jun Wei

Auto-generated profile, based on publicly available information

Jun Wei

The Ness Foundation, UHI Millennium Institute, Inverness IV3 8GY, UK

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CYChun Ye
Chun Ye
YRYan Ruan
Yan Ruan
LZLiying Zou
Liying Zou
GLGuanghui Li
Guanghui Li
CLChangdong Li
Changdong Li
WZWeiyuan Zhang
Weiyuan Zhang
Hypertensive disorders of pregnancy (HDP) are a group of medical complications in pregnancy and also a risk factor for severe pregnancy outcomes, but it lacks a large-scale epidemiological investigation in recent years. This survey represents a multicenter cross-sectional retrospective study to estimate the prevalence and analyze the risk factors for HDP among the pregnant women who had referred for delivery between January 1st 2011 and December 31st 2011 in China Mainland. A total of 112,386 pregnant women were investigated from 38 secondary and tertiary specialized or general hospitals randomly selected across the country, of which 5,869 had HDP, accounting for 5.22% of all pregnancies. There were significant differences in the prevalence of HDP between geographical regions, in which the North China showed the highest (7.44%) and Central China showed the lowest (1.23%). Of six subtypes of HDP, severe preeclampsia accounted for 39.96%, gestational hypertension for 31.40%, mild preeclampsia for 15.13%, chronic hypertension in pregnancy for 6.00%, preeclampsia superimposed on chronic hypertension for 3.68% and eclampsia for 0.89%. A number of risk factors for HDP were identified, including twin pregnancy, age of >35 years, overweight and obesity, primipara, history of hypertension as well as family history of hypertension and diabetes. The prevalence of pre-term birth, placental abruption and postpartum hemorrhage were significantly higher in women with HDP than those without HDP. The possible risk factors confirmed in this study may be useful for the development of early diagnosis and appropriate treatment of HDP.

1 August 2000 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JWJun Wei
Jun Wei
GHGwynneth P. Hemmings
Gwynneth P. Hemmings

28 July 2011 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
MRMichele F. Rega
Michele F. Rega
BWBainan Wu
Bainan Wu
JWJun Wei
Jun Wei
Ziming ZhangZiming Zhang
Ziming Zhang
JCJason F. Cellitti
Jason F. Cellitti
Maurizio PellecchiaMaurizio Pellecchia
Maurizio Pellecchia
Overexpression of antiapoptotic members of the Bcl-2 family proteins, such as Bcl-xL and Mfl-1, has been shown to be involved in resistance to chemotherapeutic drugs in many forms of cancers. Recent efforts from the Abbott Laboratories resulted in the development of the acylsulfonamide compound and clinical candidate that targets selectively Bcl-2, Bcl-xL, and Bcl-w while it is not active against Mcl-1 and Bfl-1. However, early clinical and preclinical studies suggest that pan-Bcl-2 antagonists, targeting simultaneously Mcl-1, Bcl-xL, and possibly all other four antiapoptotic Bcl-2 proteins, may result in more efficacious drugs. Here, following an NMR fragment-based approach, SAR by ILOEs, we report on compounds that exhibit nanomolar affinities for both Bcl-xL and Mcl-1 in vitro. We believe that these molecules can be used as useful starting point for the development of novel Bcl-2 antagonists, in particular targeting Mcl-1.

3 December 1996 in Human Genetics
Verified
Journal Article
Closed access
PDF file
JWJ. Wei
J. Wei
CRC. N. Ramchand
C. N. Ramchand
GHGwynneth P. Hemmings
Gwynneth P. Hemmings

1 April 2004 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
JWJ Wei
J Wei
GHG.P Hemmings
G.P Hemmings

24 January 2018 in Schizophrenia Bulletin
Verified
Journal Article
Open access
PDF file
RWRuth Whelan
Ruth Whelan
DCDavid St Clair
David St Clair
CMColette J Mustard
Colette J Mustard
PHPhilomena Hallford
Philomena Hallford
JWJun Wei
Jun Wei
A recent genome-wide association (GWA) study confirmed 108 genetic loci that were strongly associated with schizophrenia. Fifteen schizophrenia-associated genes were selected for this study based on a number of selection criteria including their high expression in both brain tissues and B-lymphocyte cells. We aimed to investigate whether individuals with schizophrenia showed different levels of plasma IgG antibodies against protein-derived fragments encoded by these 15 genes. A total of 356 plasma samples were used to analyze circulating IgG antibodies against 18 target peptide antigens using an in-house enzyme-linked immunosorbent assay. Of 18 antigens tested, 6 (derived from DPYD, MAD1L1, ZNF804A, DRD2, TRANK1, and MMP16, respectively) showed increased IgG levels and 3 (derived from TSNARE1, TCF4, and VRK2, respectively) showed decreased IgG levels in patients with schizophrenia compared with control subjects. Receiver operating characteristic (ROC) curve analysis revealed that the anti-TRANK1 IgG assay had the area under the ROC curve of 0.68 (95% CI = 0.62–0.73), with the highest sensitivity of 20.7% against specificity of 95.2% among all 18 tests. There was no difference in positivity of anti-double strand DNA IgG between the patient group and the control group and no correlation between total IgG levels and each individual IgG level tested. Although risperidone treatment showed confounding effects on overall IgG levels in the circulation (combined P = .005), anti-TRANK1 IgG levels did not appear to be significantly affected (t = 1.358, P = .176). In conclusion, this study suggests that circulating anti-TRANK1 IgG is likely to serve as a biomarker for identification of a subgroup of schizophrenia.